Related Experiment Video

Updated: Apr 17, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer

J McDermott1, A Jimeno2

  • 1Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.

Drugs of Today (Barcelona, Spain : 1998)
|February 17, 2015
PubMed

Insights

Pembrolizumab, an antibody targeting Programmed Cell Death 1 (PD-1), shows significant promise in cancer treatment by blocking immune evasion. Clinical trials demonstrate high response rates and durable effects, particularly in advanced melanoma.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Programmed cell death protein 1 (PD-1) and its ligands (PD-L1, PD-L2) regulate immune responses.
  • Abnormal expression of PD-1/PD-L1/PD-L2 in the tumor microenvironment facilitates cancer immune evasion.
  • Preclinical studies indicated PD-1 blockade suppresses tumor growth and metastasis.

Purpose of the Study:

  • To review the development of pembrolizumab, a humanized monoclonal antibody against PD-1.
  • To discuss preclinical data, pharmacokinetics, and clinical efficacy of pembrolizumab.
  • To highlight pembrolizumab's role in cancer immunotherapy.

Main Methods:

  • Review of preclinical studies on PD-1 blockade.
  • Analysis of early clinical trial data for pembrolizumab (MK-3475).
  • Examination of pharmacokinetic and efficacy data in cancer patients.

Main Results:

  • Pembrolizumab demonstrated high tumor response rates and long duration of effect in advanced melanoma.
  • Accelerated FDA approval was granted for pembrolizumab in advanced melanoma.
  • Successful outcomes observed in non-small cell lung cancer, with ongoing trials in other tumor types.

Conclusions:

  • Pembrolizumab represents a significant advancement in cancer immunotherapy by targeting the PD-1 pathway.
  • The drug has shown considerable clinical efficacy across various cancer types.
  • Further investigation into pembrolizumab's therapeutic potential is warranted.
Keywords:
Anti-PD-1 antibodyLambrolizumabMK-3475MelanomaNSCLCPembrolizumab

More Related Videos

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.4K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.9K